Skip to main content
TipRanks
Go Ultimate75% OFF

Revvity (PKN) Q3 2026 Earnings Report

1 Followers

DE:PKN Q3 2026 EPS Results

Actual EPS
EUR 1.26
Consensus EPS
EUR 1.18
Beat/Miss
Beat by +EUR 0.08
One Year Ago EPS
EUR 1.07

DE:PKN Q3 2026 Revenue Results

Actual Revenue
EUR 663.11M
Expected Revenue
EUR 632.02M
Beat/Miss
Beat by +EUR 31.09M
YoY Revenue Growth
+4.29%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/03/2026
Time
Before Open
Conference Call
Tuesday, November 3, 2026
DE:PKN Upcoming Earnings

Revvity's next earnings date is estimated for February 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:PKN Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 03, 2026|% Change Since:0.15%|
Earnings Call Sentiment|Positive

The call was strongly positive. Highlights significantly outweighed the limited challenges, with broad-based Q3 growth, improving pharma and biotech demand, expanding AI-related demand, strong cash generation, margin expansion, and multiple upward guidance revisions. The main negatives were FX pressure, APAC and China reproductive-health challenges, the pending China immunodiagnostics divestiture, and expected moderation in certain Q4 growth rates.

Company Guidance

Revvity now expects pro forma organic growth of approximately 5% in both the fourth quarter and for the full year, with FX contributing approximately 50 basis points for the full year, ACD/Labs contributing approximately 75 basis points, and 2026 pro forma revenue being approximately $2.86 billion; full year operating margins are expected to be 28.8%, net interest expense approximately $88 million, the adjusted tax rate 18%, shares outstanding 112 million, and pro forma adjusted EPS in the range of $5.40 to $5.45, which equates to approximately 12% growth year over year. For the fourth quarter, the midpoint of expected revenue is approximately $755 million, pro forma adjusted operating margins are expected to be slightly above 32%, net interest expense approximately 22 million, the adjusted tax rate approaching 20%, shares around 112 million, and the midpoint of pro forma adjusted EPS guidance $1.60; life sciences instruments are expected to grow high single digits, reagents mid single digit, Signals software closer to a mid-teens number, diagnostics mid single digits overall, immunodiagnostics up high single digits, and reproductive health at low single digits.

  • Strong Third-Quarter Organic Growth and Earnings OutperformanceRevvity delivered 7% pro forma organic growth in Q3, exceeding its mid-single-digit expectation. Pro forma adjusted operating margin was 29.4%, approximately 40 basis points above expectations, and pro forma adjusted EPS was $1.37, $0.08 above the midpoint of guidance and up 21% year over year.
  • Broad-Based Segment GrowthLife sciences grew 9% organically, with reagents up high single digits, instruments up strong mid-single digits, and Signals software growing in the high teens or upper teens. Diagnostics grew 5% organically, or in the mid-single digits, in line with expectations.
  • Improving Pharma and Biotech DemandUnderlying demand trends from pharma and biotech customers continued to improve following the policy-related headwinds experienced through much of the prior year. Pharma and biotech sales excluding Signals software grew high single digits in Q3, an acceleration from prior periods.
  • AI Demand Expanding Across the PortfolioIncremental AI-related demand continued to build beyond high-content screening and began affecting a broader portion of the portfolio. Management said AI demand is still in its early days, with potential expansion from high-content screening into high-throughput screening, imaging, detection, and in vivo applications as drug candidates progress toward IND filing.
  • High-Content Screening Momentum and Capacity ExpansionHigh-content screening revenue growth continued to accelerate despite strong year-ago comparisons, and the related instrument backlog continued to increase in Q3. Revvity added capacity and is building additional capacity to support demand that could accelerate into next year.
  • Reagents Delivered Their Strongest Performance in Several YearsLife sciences reagents grew high single digits, their strongest performance in several years across pharma, biotech, academia, and government. Performance benefited from fulfillment of bulk orders and improvement in the run-rate business; the bulk or screening-order contribution was approximately 100 basis points to reagent growth.
  • Instruments Showed Broad-Based ImprovementLife sciences instruments grew strong mid-single digits in Q3, with performance exceeding expectations and improvement across the portfolio rather than being limited to high-content screening. The detection franchise, including high-throughput screening instruments, delivered solid growth with improving momentum, and instrument backlog grew across almost every instrument group.
  • Signals Software Maintained Strong Growth and Product MomentumSignals software grew in the high teens organically, driven by strong contract renewals and continued 20%+ annual recurring revenue growth. Annualized portfolio value grew in the low double digits in Q3 and was expected to remain double-digit for the full year. Revvity launched Signals Logistics and also introduced Synthetica Biodesign, Signals AI, and the Anthropic Connector during 2026.
  • Positive Customer Traction for New Signals ProductsManagement reported very positive customer feedback and traction for the new Signals products. The company did not expect a large contribution from the new product introductions in 2026 because they require time to convert into organic growth, but said the customer response had been positive.
  • Diagnostics Innovation in Type 1 Diabetes ScreeningRevvity launched a CE IVDR-certified GSP T1D 3-Plex kit in Europe for early detection of type 1 diabetes. The assay uses a dried blood spot sample on the existing GSP platform and can screen children months or years before symptoms appear. Revvity is also advancing a broader T1D assay in collaboration with Sanofi.
  • Diagnostics Margins Improved Substantially Excluding ChinaDiagnostics adjusted operating margin was 29.9% in Q3, including a 160-basis-point headwind from the immunodiagnostics business in China that Revvity is working to divest. Excluding China, diagnostics margins increased more than 600 basis points year over year and exceeded 30% overall.
  • Operational Efficiency and Incremental Margin PotentialOperational efficiency actions taken over the prior 18 months, favorable business mix, and sales leverage drove meaningful margin expansion. Management said 40%+ incremental margins were on full display in Q3 and that low-40s-plus incremental margins remain sustainable.
  • Raised Full-Year Revenue, Margin, and EPS GuidanceRevvity raised full-year pro forma organic growth guidance to approximately 5%, compared with an initial 2% to 3% outlook and prior guidance of 4% to 5%. Full-year pro forma revenue is expected to be approximately $2.86 billion, adjusted operating margin is expected to be 28.8%, and adjusted EPS is expected to be $5.40 to $5.45, representing approximately 12% year-over-year growth.
  • Higher Fourth-Quarter OutlookFourth-quarter pro forma organic growth guidance was raised to approximately 5% from 4% previously. Expected fourth-quarter revenue is approximately $755 million at the midpoint, adjusted operating margin is slightly above 32%, and adjusted EPS is expected to be $1.60 at the midpoint.
  • Strong Free Cash Flow and Balance Sheet ProgressQ3 free cash flow was $152 million, representing 99% conversion of adjusted net income. Year-to-date free cash flow exceeded $450 million, with a 105% conversion rate. Net debt to adjusted EBITDA was 2.3x at quarter-end after retiring a €500 million note, and the company is targeting gross leverage below 3.0x and net leverage approaching 2.0x by year-end. All long-term debt is fixed rate, with a 2.8% weighted average interest rate and approximately seven years of weighted average maturity.
  • Portfolio Consolidation and Site EfficiencyRevvity consolidated key life sciences and diagnostics activities, including R&D and manufacturing, onto its modernized Hopkinton, Massachusetts campus. Management said its sites in Lübeck, Hamburg, and Hopkinton were operating better than two years earlier, with increased efficiency and collaboration.
  • Genomics England Contribution and Potential ExpansionThe Genomics England project is expected to contribute approximately $25 million on a full-year basis. Revvity remains in active negotiations to extend the existing partnership and expand it into additional areas.
  • Geographic Growth in Europe and the AmericasEurope delivered double-digit growth for the fourth consecutive quarter, and the Americas also grew double digits in Q3.

DE:PKN Earnings History

DE:PKN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 04, 20272026 (Q4)1.46-1.55――
Nov 03, 20262026 (Q3)1.181.261.0716.95% (+0.18)
Aug 04, 20262026 (Q2)1.101.281.0719.49% (+0.21)
May 05, 20262026 (Q1)0.920.950.922.97% (+0.03)
Feb 02, 20262025 (Q4)1.431.551.2919.72% (+0.25)
Oct 27, 20252025 (Q3)1.041.071.16-7.81% (-0.09)
Jun 29, 20252025 (Q2)1.041.071.11-3.28% (-0.04)
Apr 28, 20252025 (Q1)0.860.920.893.06% (+0.03)
Jan 31, 20252024 (Q4)1.241.291.1413.60% (+0.15)
Nov 04, 20242024 (Q3)1.021.161.078.47% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed